| Q38867217 | A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma |
| Q35230663 | A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer |
| Q28392105 | A multifunctional mesothelin antibody-tagged microparticle targets human mesotheliomas |
| Q47618536 | A new hope for precision medicine |
| Q27015134 | Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin |
| Q39748254 | Antitumor activity of anti-C-ERC/mesothelin monoclonal antibody in vivo |
| Q36346628 | Bispecific targeting of EGFR and uPAR in a mouse model of head and neck squamous cell carcinoma |
| Q37728639 | Chimeric antigen receptor T cells: a novel therapy for solid tumors |
| Q24651062 | Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer |
| Q26748680 | Clinical impacts of mesothelin expression in gastrointestinal carcinomas |
| Q35190612 | Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding |
| Q51807221 | Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response. |
| Q38473933 | Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor |
| Q37449036 | Future developments in the management of malignant pleural mesothelioma |
| Q38212149 | Immune therapies for malignant mesothelioma |
| Q34771909 | In vivo imaging of human malignant mesothelioma grown orthotopically in the peritoneal cavity of nude mice |
| Q36075289 | Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer |
| Q38019747 | Malignant pleural mesothelioma: from the bench to the bedside. |
| Q35815380 | Mesothelin-targeted agents in clinical trials and in preclinical development |
| Q37090793 | Mesothelin-targeted immunotherapies for malignant pleural mesothelioma |
| Q36174910 | Molecular targeted approaches for treatment of pancreatic cancer. |
| Q37355568 | Monoclonal antibodies in the treatment of pancreatic cancer. |
| Q26859274 | New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas |
| Q35023967 | Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts |
| Q64890042 | Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer a |
| Q37368203 | Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. |
| Q36273796 | Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products |
| Q37075257 | Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins |
| Q35653164 | Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy. |
| Q84565785 | Synergistic targeting of leukemia with leukotoxin and chemotherapy |
| Q37992694 | Systemic treatment of malignant pleural mesothelioma |
| Q37260408 | Systemic treatments for mesothelioma: standard and novel |
| Q37532147 | Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression |
| Q47107902 | Targeting mesothelin receptors with drug-loaded bacterial nanocells suppresses human mesothelioma tumour growth in mouse xenograft models |
| Q35317540 | Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer |
| Q52587886 | The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review. |
| Q21198791 | The detection, treatment, and biology of epithelial ovarian cancer |
| Q27314606 | The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy |
| Q64122281 | Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells |
| Q37133208 | Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel |